We observed that PKM2 targeting by both strategies had decreased cytoplasmic and increased nuclear PKM2 enzyme activity in patient-derived established NSCLC cell lines, which also corroborated with PKM2 expression examined by ICC assay in vitro. The gene discussed is PKM; the disease is intrahepatic cholangiocarcinoma.